Most importantly, treatment of the invasive mammary tumour cells with the combination of CXCL12 and CCL19 at suboptimal concentrations, elicited a very strong synergistic response in inhibiting cAMP, paralleling results obtained in cells from advanced primary human breast cancer. Here, CXCL12 is linked to breast carcinoma.